Filing Details
- Accession Number:
- 0001225208-18-004459
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-27 19:38:48
- Reporting Period:
- 2018-02-24
- Accepted Time:
- 2018-02-27 19:38:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 78003 | Pfizer Inc | PFE | Pharmaceutical Preparations (2834) | 135315170 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1693493 | Kirsten Lund-Jurgensen | Pfizer Inc.-Corp. Secretary 235 East 42Nd St. New York NY 10017 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-24 | 15,957 | $18.90 | 36,959 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-24 | 3,692 | $36.26 | 33,267 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-02-24 | 5,091 | $35.98 | 28,176 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-02-26 | 896 | $37.09 | 27,280 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2018-02-26 | 9,510 | $37.19 | 17,770 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Appreciation Rights | Disposition | 2018-02-24 | 15,957 | $0.00 | 15,957 | $18.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-02-24 | 2018-02-24 | No | 4 | M | Direct |
Footnotes
- The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- Price is the closing price of Pfizer common stock on February 23, 2018
- The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
- The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).
Billionaire Hedge Funds
